We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
3 watching
Current Price
$5.89
$1.24
(26.67%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
54.47M
52-Week High
8.255
52-Week Low
1.325
Average Volume
11.76M
Dividend Yield
--
P/E Ratio
--
Market Capitalization54.47M
52-Week High8.255
52-Week Low1.325
Average Volume11.76M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer s disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
7hours ago
Thinking about buying stock in Carvana, BioVie, Airbnb, RLX Technology, or Melco Resorts & Entertainment? Thinking about buying stock in Carvana, BioVie, Airbnb, RLX Technology, or Melco Resorts & Entertainment? PR Newswire NEW YORK, Dec. 7, 2022 NEW YORK, Dec. 7, 2022 /PRNewswire...
Globe Newswire
8days ago
Company is Opting to Increase Study Size to 400 due to Fast Enrollment PaceCARSON CITY, Nev., Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative ...
Ticker Report
1month ago
BioVie Inc. (NASDAQ:BIVI Get Rating) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 123,900 shares, a drop of 11.1% from the September 30th total of 139,300 shares. Approximately 7.3% of the shares of...
PR Newswire
3 months ago
Thinking about buying stock in Spero Therapeutics, Quoin Pharmaceuticals, BioVie, Reviva Pharmaceuticals, or Avaya? Thinking about buying stock in Spero Therapeutics, Quoin Pharmaceuticals, BioVie, Reviva Pharmaceuticals, or Avaya? PR Newswire NEW YORK, Sept. 7, 2022 NEW YORK, Sept. 7, 2022...
Accesswire
3 months ago
ORLANDO, FL / ACCESSWIRE / August 25, 2022 / RedChip Companies will air a new interview with BioVie Inc. (NASDAQ:BIVI) ('BioVie' or 'Company'), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$5.89
$1.24
(26.67%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00